48
Participants
Start Date
July 6, 2017
Primary Completion Date
May 7, 2021
Study Completion Date
May 7, 2021
TWB-103 Group
Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Placebo Group
Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
Tri-Service General Hospital, Taipei
Nippon Medical School, Tokyo
Tokyo Medical University, Tokyo
A2 Healthcare Taiwan Corporation
INDUSTRY
Transwell Biotech Co., Ltd.
INDUSTRY